Plasma Exchange for Autoimmune Autonomic Failure
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00359346|
Recruitment Status : Completed
First Posted : August 2, 2006
Last Update Posted : July 2, 2017
This study will explore whether an antibody is influencing the autonomic nervous system, and if its removal will eliminate signs and symptoms of failure in that system. The autonomic nervous system is responsible for many automatic changes involved in everyday activities, such as standing up, digesting food, and exercising in the heat. Antibodies fight germs but sometimes cause health problems. Removal of the antibody is done through a procedure called a plasma exchange.
Patients with primary chronic autonomic failure and a circulating antibody to what is called the neuronal nicotinic receptor may be eligible for this study. To be eligible, patients will have participated in an earlier study, protocol number 03-N-0004. Patients will undergo tests and procedures that include an electrocardiogram, and blood collection for hepatitis, HIV, and pregnancy. Blood will be tested for a complete blood count, clotting factors, and chemistries. There will also be tests for liver function, kidney function, cortisol, and thyroid. Participants will be tested for signs and symptoms of autonomic failure, and will be asked to complete questionnaires about various symptoms before the plasma exchange, 1 or 2 weeks afterward, and then monthly or bimonthly for up to 1 year. Patients will undergo a series of other tests. In one test, a patient is upright and blows against a resistance (Valsalva maneuver). The quantitative sudomotor axon reflex test (QSART) uses iontophoresis, involving application of acetylcholine, a chemical messenger, and a small amount of electricity. QSART examines the regulation of sweating, a particular aspect of the autonomic nervous system. There will be a test using edrophonium, given intravenously (IV), to evaluate that drug's effects on the heart, skin, glands, gastrointestinal activity, bladder tone, and salivation. A glucagon test, also by IV, will show patients' ability to release the hormone adrenaline.
The plasma exchange will be performed by use of an automated cell separator. Patients' blood will be removed continuously through a needle in the arm. Blood cells will be separated from the plasma by a spinning process and continuously returned to circulation through a needle in the patients' opposite arm. Blood cells that are returned will be mixed with albumin, a sterile replacement solution. A blood thinner, citrate, will be given, to prevent clotting of blood. This whole procedure will take about 2 hours. Patients will typically undergo five exchange procedures in about 10 days while they are inpatients at the NIH Clinical Center. The amount of plasma removed in a single session and the number of sessions will be set by the NIH Blood Bank. It is expected that patients' autonomic failure will improve after several days of starting the plasma exchange. Testing for symptoms of autonomic failure and autonomic function testing will occur about 1 month after the plasma exchange and monthly or bimonthly for up to 1 year. For each visit of testing, patients will be inpatients for about 2 days. If autonomic failure recurs, patients may have a second plasma exchange, with the same follow-up tests, for about 1 year.
|Condition or disease|
|Plasma Exchange Autonomic Failure|
Background: Until recently, it was thought that primary chronic autonomic failure occurring without central neurodegeneration (pure autonomic failure, PAF) reflected diffuse loss of catecholamine-producing cells (sympathetic noradrenergic nerves and adrenomedullary chromaffin cells) outside the brain. Rarely, however, PAF patients have clinical laboratory findings suggesting decreased post-ganglionic nerve traffic in intact autonomic nerves, rather than denervation. To date, all of four such patients have also had a high titer of a circulating antibody to the nicotinic receptor mediating ganglionic neurotransmission. In one case, studied by another group, plasma exchange reversed signs and symptoms of autonomic failure, consistent with the antibody being pathogenic.
Purpose: In this Protocol, we will carry out plasma exchange in patients we identify as having PAF, intact cardiac noradrenergic innervation, and a circulating antibody to the neuronal nicotinic receptor, to determine whether antibody pathogenicity is a consistent finding in this condition. We will assess the extent of relationship between symptoms, signs, and clinical laboratory indices of autonomic function with the titer of the antibody and obtain abundant plasma for antibody characterization and target protein identification.
Methods: Autonomic function testing will be done before plasma exchange, 1-2 weeks after plasma exchange, and monthly or bi-monthly thereafter for up to one year. Plasma exchange may be repeated once, when symptoms of autonomic failure return as the antibody level builds up, to verify in individual patients whether repetition of plasma exchange produces reproducible amelioration of clinical and laboratory measures of autonomic failure.
|Study Type :||Observational|
|Enrollment :||3 participants|
|Official Title:||Plasma Exchange for Autoimmune Autonomic Failure|
|Study Start Date :||July 14, 2006|
|Study Completion Date :||April 16, 2009|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00359346
|United States, Maryland|
|National Institutes of Health Clinical Center, 9000 Rockville Pike|
|Bethesda, Maryland, United States, 20892|